Commission Directive 2011/6/EU [Commission Directive 2011/6/EU of 20 January 2011 amending Council Directive 91/414/EEC to include buprofezin as active substance (OJ L 18, 21.1.2011, p. 38, ELI: http://data.europa.eu/eli/dir/2011/6/oj).] included buprofezin in Annex I to Directive 91/414/EEC as an active substance until 31 January 2021 and it was subsequently included in Part A of the Annex to Implementing Regulation (EU) No 540/2011. The approval of buprofezin was extended four times, most recently by Commission Implementing Regulation (EU) 2025/1489 [Commission Implementing Regulation (EU) 2025/1489 of 24 July 2025 amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances ametoctradin, Beauveria bassiana strains ATCC 74040 and GHA, buprofezin, clodinafop, copper compounds, cyflumetofen, daminozide, flupyradifurone, Helicoverpa armigera nucleopolyhedrovirus, mandestrobin, mandipropamid, metam, pyraclostrobin, rescalure, Spodoptera littoralis nucleopolyhedrovirus, Streptomyces lydicus strain WYEC 108, Trichoderma asperellum strain T34 and Trichoderma atroviride strain I-1237 (OJ L, 2025/1489, 25.7.2025, ELI: http://data.europa.eu/eli/reg_impl/2025/1489/oj).] until 15 December 2026.
Recital 10, Regulation (EU) 2026/2348
In force
Commission Implementing Regulation (EU) No 540/2011 of 25 May 2011 implementing Regulati…Law
- celex=31991L0414
- celex=32011L0006
- num:eu=1991/414